Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs (2015)

  • Authors:
  • USP affiliated authors: FUJITA, ANDRÉ - IME
  • USP Schools: IME
  • DOI: 10.1038/srep13076
  • Subjects: BIOINFORMÁTICA; NEOPLASIAS PULMONARES
  • Language: Inglês
  • Imprenta:
  • Source:
    • Título do periódico: Scientific Reports
    • ISSN: 2045-2322
    • Volume/Número/Paginação/Ano: article number 13076, 13 p., published online: 13 Aug. 2015
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1038/srep13076 (Fonte: oaDOI API)
    • Este periódico é de acesso aberto
    • Este artigo é de acesso aberto
    • URL de acesso aberto
    • Cor do Acesso Aberto: hybrid
    • Licença: cc-by
    Versões disponíveis em Acesso Aberto do: 10.1038/srep13076 (Fonte: Unpaywall API)

    Título do periódico: Scientific Reports

    ISSN: 2045-2322

    • Melhor URL em Acesso Aberto:


    • Outras alternativas de URLs em Acesso Aberto:


        • Página do artigo
        • Evidência: oa journal (via doaj)
        • Licença: cc-by
        • Versão: publishedVersion
        • Tipo de hospedagem: publisher




        • Página do artigo
        • Evidência: oa repository (via pmcid lookup)
        • Licença:
        • Versão: publishedVersion
        • Tipo de hospedagem: repository


        • Página do artigo
        • Link para o PDF
        • Evidência: oa repository (via OAI-PMH title and first author match)
        • Licença: cc-by-nc-nd
        • Versão: submittedVersion
        • Tipo de hospedagem: repository


    Informações sobre o Citescore
  • Título: Scientific Reports

    ISSN: 2045-2322

    Citescore - 2017: 4.36

    SJR - 2017: 1.533

    SNIP - 2017: 1.245


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    IME2710136-10PROD-2710136
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      NAKATA, Asuka; YOSHIDA, Ryo; YAMAGUCHI, Rui; et al. Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. Scientific Reports, London, p. 13 , 2015. Disponível em: < http://dx.doi.org/10.1038/srep13076 > DOI: 10.1038/srep13076.
    • APA

      Nakata, A., Yoshida, R., Yamaguchi, R., Yamauchi, M., Tamada, Y., Fujita, A., et al. (2015). Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. Scientific Reports, 13 . doi:10.1038/srep13076
    • NLM

      Nakata A, Yoshida R, Yamaguchi R, Yamauchi M, Tamada Y, Fujita A, Shimamura T, Imoto S, Higuchi T, Nomura M, Kimura T, Nokihara H, Higashiyama M, Kondoh K, Nishihara H, Tojo A, Yano S, Miyano S, Gotoh N. Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs [Internet]. Scientific Reports. 2015 ; 13 .Available from: http://dx.doi.org/10.1038/srep13076
    • Vancouver

      Nakata A, Yoshida R, Yamaguchi R, Yamauchi M, Tamada Y, Fujita A, Shimamura T, Imoto S, Higuchi T, Nomura M, Kimura T, Nokihara H, Higashiyama M, Kondoh K, Nishihara H, Tojo A, Yano S, Miyano S, Gotoh N. Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs [Internet]. Scientific Reports. 2015 ; 13 .Available from: http://dx.doi.org/10.1038/srep13076

    Referências citadas na obra
    Jemal A. et al. Global cancer statistics. CA Cancer J Clin 61, 69–90 (2011).
    Fossella F. et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 21, 3016–24 (2003).
    Pignon J. P. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26, 3552–9 (2008).
    Surmont V. et al. Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study. J Oncol 2009, 457418 (2009).
    Bezjak A. et al. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol 26, 5052–9 (2008).
    Strauss G. M. et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26, 5043–51 (2008).
    Nakata A. & Gotoh N. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opin Ther Targets 16, 771–81 (2012).
    Lynch T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129–39 (2004).
    Paez J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–500 (2004).
    Pao W. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101, 13306–11 (2004).
    Mitsudomi T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11, 121–8 (2010).
    Mok T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361, 947–57 (2009).
    Kobayashi S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352, 786–92 (2005).
    Kwak E. L. et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102, 7665–70 (2005).
    Pao W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2, e73 (2005).
    Bean J. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104, 20932–7 (2007).
    Engelman J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–43 (2007).
    Yamada T. et al. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res 16, 174–83 (2010).
    Yano S. et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68, 9479–87 (2008).
    Yamauchi M. et al. N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells. Am J Cancer Res 1, 823–33 (2011).
    Turke A. B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77–88 (2010).
    Reya T. & Clevers H. Wnt signalling in stem cells and cancer. Nature 434, 843–50 (2005).
    Mazieres J., He B., You L., Xu Z. & Jablons D. M. Wnt signaling in lung cancer. Cancer Lett 222, 1–10 (2005).
    Ohgaki H. et al. APC mutations are infrequent but present in human lung cancer. Cancer Lett 207, 197–203 (2004).
    Akiri G. et al. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 28, 2163–72 (2009).
    Bravo D. T. et al. Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer. BMC Cancer 13, 316 (2013).
    Nakashima T. et al. Wnt1 overexpression associated with tumor proliferation and a poor prognosis in non-small cell lung cancer patients. Oncol Rep 19, 203–9 (2008).
    Fukui T. et al. Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene 24, 6323–7 (2005).
    Gao Z. et al. Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells. Oncol Rep 22, 1479–84 (2009).
    Na Y., Lee S. M., Kim D. S. & Park J. Y. Promoter methylation of Wnt antagonist DKK1 gene and prognostic value in Korean patients with non-small cell lung cancers. Cancer Biomark 12, 73–9 (2012).
    Noro R. et al. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer 6, 277 (2006).
    McCubrey J. A. et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 5, 2881–911 (2014).
    Jho E. H. et al. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22, 1172–83 (2002).
    Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov 13, 513–32 (2014).
    Yano S. et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 6, 2011–7 (2011).
    Shigematsu H. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97, 339–46 (2005).
    Soda M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–6 (2007).
    Kohno T. et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18, 375–7 (2012).
    Lipson D. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18, 382–4 (2012).
    Takeuchi K. et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 18, 378–81 (2012).
    Reya T. et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423, 409–14 (2003).
    Vermeulen L. et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12, 468–76 (2010).
    Schade B. et al. beta-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. Cancer Res 73, 4474–87 (2013).
    Murohashi M. et al. An FGF4-FRS2alpha-Cdx2 axis in trophoblast stem cells induces Bmp4 to regulate proper growth of early mouse embryos. Stem Cells 28, 113–21 (2010).
    Storey J. D. A direct approach to false discovery rates. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 64, 479–98 (2002).
    Zeeberg B. et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biology 4, 1–8 (2003).
    Barnard G. A new test for 2 × 2 tables. Nature 156, 177 (1945).
    Barnard G. A. Significance tests for 2 × 2 tables. Biometrika 34, 123–38 (1947).